Purification and Identification of Brain-Derived Neurotrophic Factor from Human Serum

Rosenfeld, Robert; Zeni, Luigi; Haniu, Mitsuru; Talvenheimo, Jane; Radka, Susan F.; Bennett, L. G.; Miller, James A.; Welcher, Andy

doi:10.1006/prep.1995.1062

Cited by 141 publications

(91 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, anti-depressant treatment of MDD patients increases serum BDNF levels in responders and remitters significantly more than in non-responders, but insufficient data are available for comparing plasma levels in responders versus non-responders (Polyakova et al 2015). This would be an important comparison, as plasma and serum BDNF levels show at least a 100-fold difference (Rosenfeld et al 1995). The results of prior meta analyses reported similar results.…”

Section: Peripheral Biomarkersmentioning

confidence: 99%

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Fabbri

Hosák

Mößner

et al. 2016

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under-or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in anti-depressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-a receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

show abstract

Section: Peripheral Biomarkersmentioning

confidence: 99%

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Fabbri

Hosák

Mößner

et al. 2016

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…Data about serum BDNF concentrations in major depression are conflicting, some authors reported levels as decreased [Karege et al 2002[Karege et al , 2005Shimizu et al 2003;Aydemir et al 2006;Monteleone et al 2008], and others as unchanged [Ziegenhorn et al 2007], compared with the healthy controls. Serum levels of BDNF have been found to be 200-fold higher than plasma levels [Rosenfeld et al 1995]. This difference could reflect the amount of BDNF stored in platelets.…”

Section: Introductionmentioning

confidence: 95%

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Kotan¹,

Sarandöl²,

Kırhan³

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Abstract:Objective: Brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and leptin have been hypothesized to be involved in the neurobiology of depression. The aim of this study was to investigate BDNF, VEGF and leptin levels in patients with severe melancholic depression. Methods: A total of 40 drug-free patients with major depressive disorder (MDD) with melancholic features and 40 healthy controls were included in the study. Demographic information, psychiatric evaluation and physical examination were documented for both groups. Serum BDNF, VEGF levels were determined by enzyme-linked immunosorbent assay and leptin with radioimmunoassay methods. The Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were applied to the patients. Results: There were no significant differences in serum BDNF, VEGF and leptin levels between the patient and control groups. There was a negative correlation between BDNF levels and the number of depressive episodes. It was noted that VEGF levels decreased with increasing severity of depression. Conclusions: These findings suggest that BDNF levels might be associated with the recurrence of depression and VEGF levels might be a determinant of the severity of depression.

show abstract

“…First evidence for the presence of BDNF in human circulation emerged a decade ago (Rosenfeld et al 1995).…”

Section: Introductionmentioning

confidence: 99%

Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm

Begliuomini

Lenzi²,

Ninni³

et al. 2008

Journal of Endocrinology

136

View full text Add to dashboard Cite

Expression and secretion of neurotrophins, including brainderived neurotrophic factor (BDNF), are regulated also by neuronal activity. Data available in the literature suggest that BDNF central levels are influenced by light and dark. Diurnal changes of BDNF mRNA and protein contents have been demonstrated in the rat central nervous system. Based on these pieces of evidence, we investigated the hypothesis of a possible diurnal variation of BDNF circulating levels in human males. Moreover, we looked for a possible correlation with cortisol circadian rhythm, since both BDNF and cortisol are implicated in the maintenance of cerebral functions. In this study, 34 healthy young male volunteers were included. Five blood samples were drawn from each subject thrice in a month at regular 4-h intervals (0800, 1200, 1600, 2000, and 2400 h). BDNF and cortisol were measured in all samples. BDNF was determined by ELISA method. Our results show that plasma BDNF levels, as well as cortisol levels, are significantly higher in the morning when compared with the night (P!0 . 001), with a trend of constant decrease during the day. Furthermore, plasma BDNF and cortisol are positively correlated (Spearman indexZ0 . 8466). The present study is the first to demonstrate the presence of a diurnal rhythm of BDNF in humans. Moreover, the correlation found out between BDNF and cortisol circadian trend allows us to speculate that these two factors may be physiologically co-regulated, in order to maintain the homeostasis of integrated cerebral activities.

show abstract

Purification and Identification of Brain-Derived Neurotrophic Factor from Human Serum

Cited by 141 publications

References 0 publications

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Plasma brain-derived neurotrophic factor daily variations in men: correlation with cortisol circadian rhythm

Contact Info

Product

Resources

About